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Allogeneic hematopoietic stem cell transplantation is
the only curative option for high risk adult acute
lymphoblastic leukemia (adALL). In the absence of an HLA
identical sibling donor, HLA matched unrelated donor or
HLA mismatched cord blood are alternative stem cell
sources. However, very few data on the outcomes after
umbilical cord blood transplantation (UCBT) for adALL
using myeloablative (MAC) or reduced intensity (RIC)
conditioning regimens have been reported. We conducted
a retrospective survey on the outcomes after UCBT for
adALL and a more speciﬁc analysis for patients with
cytogenetic data transplanted in remission with either
MAC or RIC. From 1996 to 2011, 433 adult patients (pts)
received a UCBT for ALL. Overall 2-year LFS was 37% for
pts in ﬁrst complete remission (CR1, n¼199), 32% for CR2
(n¼138) and 9% for advanced disease (n¼96). Complete
cytogenetic data at diagnosis was available for 316 pts, of
whom 251 were transplanted in CR1 (63%, n¼157) or CR2
(37%, n¼94). Median age at UCBT was 33 years (18 to 66)
and 76% of the pts (n¼191) had an abnormal karyotype at
diagnosis. Pts were analyzed according to the presence of
t(9;22) as Phþ (n¼115) and Ph- (n¼136). Double CBT was
performed in 109 pts (43%) and the median total nucle-
ated cell dose at freezing was 4.02x107/kg. Most pts
received CBU with 1 (n¼74) or 2 (n¼136) HLA disparities.
MAC was given to 177 pts (70%) and 73 (30%) received
RIC. Overall 2-year leukemia- free survival (LFS) was
363%; 37% for Ph- and 35% for Phþ pts (p¼NS). On
multivariate analysis, 3 factors were associated with
improved LFS: age <44 years (HR: 0.6, p¼0.004), CR1 at
transplant (HR: 0.6, p¼0.005) and use of RIC (HR: 0.6,
p¼0.015).
In pts transplanted with MAC (n¼177), most used
regimens were Cy-TBI (27%) and BuþFluþThio (25%).
Median follow-up (FU) was 26 and 35 months for CR1
(n¼107) and CR2 (n¼70). Cumulative incidence (CI) of 60-
day neutrophil recovery was 87% (CR1) and 83% (CR2);
acute GVHD was 43% and 37%, respectively. Two-year CI of
NRM was 41% and 49%; 2-year RI was 24% and 22% for
CR1 and CR2, respectively. Two-year LFS was 35% for CR1
and 30% for CR2. No factor was found to be associated
with LFS, relapse or NRM.In pts transplanted with RIC (n¼73), CyþFluþTBI was
used in 74% (n¼54). Median FU was 31 and 34 months and
median age was 50 and 39 years for CR1 (n¼49) and CR2
(n¼24), respectively. At 2 years, CI of NRMwas 22% (CR1) and
17% (CR2). Two-year RI was 30% and 47%, respectively. Two-
year LFS was 49% (CR1) and 36% (CR2). For pts in CR1,
univariate analysis showed that younger age (< 50 years)
was associated with improved LFS (62% x 36%, p¼0.042) and
lower NRM.
UCBT is an option to treat high risk adALL. MAC was
associated with a LFS comparable with that reported with
other stem cell sources, but strategies to reduce toxicity are
still needed. Results with RIC are encouraging and may be
considered in younger pts. Importantly, in this large series
outcomes after UCBT were similar for Phþ and Ph- ALL.34
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Unrelated cord blood (UCB) is an alternative source of
allogeneic hematopoietic stem cell transplantation (HSCT)
for adults with acute leukemia lacking a HLA matched donor.
Double cord blood unit (dUCBT) has been increasingly used
over single CB unit (sUCBT) after reduced intensity condi-
tioning regimen (RIC). We analyzed 360 adults with ALL (n¼
77) or AML (n¼238) in CR1 (n¼212) and CR2 (n¼148)
transplanted with a sUCBT (n¼131) or a dUCBT (n¼229) after
RIC. Only patients (pts) transplanted with a sUCBT with
a minimum of 2.5x107/kg total nucleated cells (TNC) were
included. Pts were transplanted from 2005-2011 in EBMT
centers. Comparing the recipients of sUCBT and dUCBT in
CR1, there were no statistical differences according to age,
diagnosis (AML or ALL), weight, CMV serostatus, cytogenetic
risk, number of HLA incompatibilities. However, dUCBT were
performed more recently (2009 vs 2008), the time from CR1
to transplant was longer (142 days vs 121 days), more
frequently transplanted with CYþFLUþTBI2Gy (87% vs 68%),
lower frequency of ATG use (21% vs 35%) and they received
higher number of TNC collected (5x107/kg vs 3.9x107/kg) or
infused (4x107/kg vs 3.1x107/kg). Median follow-up was 23
months in both groups.
Cumulative incidence (CI) of 60 days neutrophil recovery
was 82% for dUCBT and 76% for sUCBT (p¼0.86); frequency of
full donor chimerism at day 100 was not statistically
different between dUCBT (81%) and sUCBT (86%). At day 100,
CI of acute GVHD (grade II-IV) was 35% in both groups,





R+/D+ 109 (27%) 104 (33.4%) 0.1665
R+/D- 86 (21.3%) 54 (17.4%) 0.5219*
R-/D+ 46 (11.4%) 41 (13.2%)
R-/D- 162 (40.2%) 112 (36%)
HLA
MRD 182 (45.2%) 171 (55%) 0.0092
Mismatched
or Unrelated
221 (54.8%) 140 (45.0%)
Stem Cell Source
Bone Marrow 76 (18.9%) 52 (16.7%) 0.4602
PBSC 327 (81.1%) 259 (83.3%)
CMV Prophylaxis
Yes 64 (15.9%) 45 (14.5%) 0.6031































16 (4%) 7 (2.3%) 0.197
TCD indicates, T-cell depleted transplant; CONV, unmodiﬁed transplant;
CMV, cytomegalovirus; R+, recipient seropositive; R-, recipient seronega-
tive; D+, donor seropositive; D-, donor seronegative; HLA, human leukocyte
antigen; MRD, matched related donor; PBSC, peripheral blood stem cells;
* Comparing recipient seropositivity between TCD and unmodiﬁed graft
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but increased incidence of grade II aGVHD after dUCBT (28%)
compared to 17% after sUCBT (p¼0.05). CI of chronic GvHD at
2 years was 21% after dUCBTand 12% after sUCBT (p¼0.15). At
2 years, CI of non relapse mortality (NRM) was 28% after
dUCBT and 30% after sUCBT (p¼0.87). CI of 2y RI was 21%
after dUCBT whereas it was 38% after sUCBT (p¼0.03). In
a multivariate analysis adjusting for the differences between
the 2 groups, dUCBT was associated with lower RI compared
to sUCBT (HR¼0.74, p¼0.01). Therefore, there was an
improved 2-y LFS after dUCBT (51%) compared to sUCBT
(32%; p¼0.03). This was conﬁrmed in a multivariate analysis
(HR¼0.64, p¼0.04).
Concerning pts transplanted in CR2 (n¼148), there were
no differences of outcomes after dUCBT (n¼93) or sUCBT
(n¼55). At 2y, LFS was 40% after dUCBT and 48% after sUCBT
(p¼0.32). In a subgroup analysis of dUCBT (n¼118) and
sUCBT (n¼51) recipients using the same conditioning
regimen (CYþFLUþTBI2Gy), 2 y LFS were 54% and 33%
respectively (p¼0.05).
In this retrospective comparative based registry analysis,
in AL pts transplanted in CR1, neutrophil recovery, GVHD and
NRM were not statistically different after RIC-dUCBT or RIC-
sUCBT, however, dUCBT recipients had decreased RI and
improved LFS. For AL pts transplanted in CR2, there was no
beneﬁt of using dUCBT when compared to sUCBT.
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Cytomegalovirus (CMV) is a major cause of mortality and
morbidity in hematopoietic stem cell transplantation (HSCT).
Transfer of CMV-speciﬁc T-cells from the donor is important
for the control of CMV replication after HSCT. In this study,
we compared incidence and kinetics of CMV infection and
CMV disease between T-cell depleted (TCD) and unmodiﬁed
(CONV) HSCT.
Methods: The cohort consisted of 714 adult HSCT recipients
of bone marrow or peripheral blood stem cell allografts from
September 1999 to March 2010 at Memorial Sloan-Kettering
Cancer Center. Patients were followed until July 2012. TCD
recipients did not receive any additional prophylactic
medicinal immunosuppression for graft-vs-host disease
(GvHD). CMV infection was monitored by PP65 antigenemia
assay (CMV Ag) if recipient or donor were CMV seropositive
and the information was prospectively stored in a comput-
erized database. Prior to 2007, recipients of mismatched
or unrelated allografts were eligible for CMV prophylaxis
if recipient or donor were CMV seropositive. Anti-CMV
agents were given to patients who had >¼ 2 cells per slide
(cps) on 1 occasion or 1 cps on >¼ 2 consecutive occasions.
Relapse, second transplant, death, and study termination
(April, 2012) were considered as competing risk for CMV
reactivation.
Results: Four hundred and three (56.5%) patients received
TCD grafts and 311 (43.6%) received unmodiﬁed grafts
(CONV). Recipient CMV seropositivity was 48.3% in TCD and
50.8% in CONV (p¼0.5219). There are 221 (54.8%) TCD and140 (45.0%) CONV patients received allograft from mis-
matched or unrelated donors (p¼0.0092). Sixty-four (15.9%)
TCD and 45 (14.5%) CONV patients received CMV prophylaxis
(p¼0.6031). CMV infections occurred in 135 (33.5%) TCD and
86 (27.7%) CONV patients. Two hundred and ﬁve (92.8%) of
the 221 infections developed by day þ100 post-transplant.
CMV infections requiring antiviral treatment occurred in 111
(27.5%) TCD and 64 (20.6%) CONV patients (p¼0.0319). Days
from HSCT to ﬁrst CMV infection were median 31 in TCD and
41.5 in CONV (p<0.0001). Maximum cps were median 5
(range 1 to 100) cps in TCD and 3 (1 to 100) cps in CONV
(p¼0.0159). Duration of reactivation was median 11 days in
TCD and 8 days in CONV patients (p¼0.0042). CMV disease
was diagnosed in 4% in TCD patients and 2.3% in CONV
patients (p¼0.197).
Conclusion: 1) Rates of CMV infection were similar in TCD
and CONV allogeneic HSCT; 2) In contrast, the kinetics of
CMV replication were different between the 2 groups: In
TCD, CMV infection occurred earlier, with higher peak level,
and longer duration of viremia 3) Rates of CMV disease were
low and similar between TCD and CONV (4% and 2.3%
respectively) Our data suggests that preemptive treatment
based on antigenemia is similarly effective for prevention of
CMV disease in TCD and CONV allografts.
